Efficacy, Safety and Tolerability of Switching From Glucagon-like Peptide-1 Receptor Agonists (GLP-1RA) to Maridebart Cafraglutide in Adults With Obesity or Overweight (MARITIME-SWITCH)

NCT07575399 · clinicaltrials.gov ↗

PHASE3

Phase

NOT_YET_RECRUITING

Status

300

Enrollment

INDUSTRY

Sponsor class

Conditions

Obesity or Overweight

Interventions

DRUG: Maridebart Cafraglutide

Sponsor

Amgen